Is Physical Activity, Obesity, and Ethnicity Associated With the Tethering and Migration of Pro-inflammatory Monocytes?
Is Physical Activity Associated With the Tethering and Migration of Pro-inflammatory Monocytes in White European and South Asian Males With and Without Central Obesity.
調査の概要
詳細な説明
Central obesity is associated with an increased risk of cardiovascular disease. Further, south Asians have been shown to be at an increased risk of cardiovascular disease compared to white Europeans.
Cardiovascular disease is underpinned by inflammation. Evidence suggests that people with obesity have a more pro-inflammatory and pro-migratory monocyte profile compared with individuals who are lean. The excessive monocyte migration contributes to metabolic dysfunction over time, increasing the risk of chronic disease. However, there is no evidence in south Asians.
One modifiable risk factor which may be able to influence this is physical inactivity, with higher levels of physical activity being associated with reduced inflammation. However, although south Asians are more at risk of cardiovascular disease than white Europeans, evidence suggests south Asians are also less physically active than white Europeans.
The investigators are looking to recruit south Asian and white European men who are lean or have central obesity to investigate 1) is there an association between ethnicity and the tethering and migration of pro-inflammatory monocytes? 2) is there an association between central obesity and the tethering and migration of pro-inflammatory monocytes, and is there an interaction with ethnicity? 3) do higher levels of physical activity influence the tethering and migration of pro-inflammatory monocytes, and is this influenced by ethnicity or central obesity?
To investigate this, the investigators are looking to recruit south Asian and white European men who are either centrally obese or lean. The investigators require 1 blood sample and the participants to wear an activity monitor for 7 days.
Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood sample. Then, the investigators will quantify the migratory capacity of PBMCs to a fixed chemokine gradient over time. Further, the investigators will phenotype the monocytes to indicate the characteristics of the monocytes that migrate towards the chemokine mix.
The activity monitor will quantify habitual physical activity, which will be used in the statistical analyses to investigate whether physical activity may influence the response.
It is important to investigate as it will further scientific knowledge on the underpinnings of chronic disease and enable a better understanding on the role of physical activity to potentially reduce the risk.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Loughborough、イギリス、LE113TU
- National Centre for Sport and Exercise Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Non-smokers (including vaping)
- Not currently dieting
Exclusion Criteria:
- Musculoskeletal injury that has affected normal ambulation within the last month;
- Any muscle or bone injuries that influence physical activity
- Free from heart conditions and blood disorders
- Weight fluctuation greater than 3kg in the previous 3 months
- Taking anti-inflammatory medication
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
South Asians who are lean
The south Asian group who are lean will be of south Asian ethnicity and a waist circumference <90cm. The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes. Metabolic markers will be analysed and presented in a participant characteristics table. |
7 days habitual physical activity via accelerometry (ActiGraph GT3x).
Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
|
|
South Asians with central obesity
The south Asian group with central obesity will be of south Asian ethnicity and a waist circumference of 90cm or greater. The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes. Metabolic markers will be analysed and presented in a participant characteristics table. |
7 days habitual physical activity via accelerometry (ActiGraph GT3x).
Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
|
|
White Europeans who are lean
The white European group who are lean will be of white European ethnicity and a waist circumference <94cm. The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes. Metabolic markers will be analysed and presented in a participant characteristics table. |
7 days habitual physical activity via accelerometry (ActiGraph GT3x).
Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
|
|
White Europeans with central obesity
The white European group with central obesity will be of white European ethnicity and a waist circumference of 94cm or greater. The group will receive an accelerometer (Actigraph GT3x) to wear for 7 days to measure habitual physical activity. They will then provide a single blood donation in a fasted state which we will use to quantify the migration of pro-inflammatory monocytes towards adipose tissue specific media. This will then be compared to the other 3 groups to investigate the interaction between ethnicity, central obesity, and physical activity with the migration of pro-inflammatory monocytes. Metabolic markers will be analysed and presented in a participant characteristics table. |
7 days habitual physical activity via accelerometry (ActiGraph GT3x).
Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentrations of classical monocytes.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as cells/uL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentrations of intermediate monocytes.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as cells/uL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentrations of non-classical monocytes.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as cells/uL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentrations of CCR2+ monocytes.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as cells/uL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentrations of CCR2+ classical monocytes.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as cells/uL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentrations of CCR5+ monocytes.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as cells/uL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of classical monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of intermediate monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of non-classical monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of CCR2+ monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of CCR2+ classical monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of CCR5+ monocytes that migrated.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of classical monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of intermediate monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of non-classical monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of CCR2+ monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of CCR2+ classical monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Number of CCR5+ monocytes that tethered.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
Presented as number of cells.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
CCR2+ receptor expression.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
CCR5+ receptor expression.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via flow cytometry.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentration of total cholesterol.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of total cholesterol.
Presented as mmol/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of high-density lipoprotein cholesterol (HDL).
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of high-density lipoprotein cholesterol.
Presented as mmol/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of low-density lipoprotein cholesterol (LDL).
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of low-density lipoprotein cholesterol.
Presented as mmol/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of triacylglycerol.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of triacylglycerol.
Presented as mmol/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of glucose.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of glucose.
Presented as mmol/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of c-reactive protein.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of c-reactive protein.
Presented as mg/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of interleukin-6.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of interleukin-6.
Presented as pg/mL.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Concentration of non-esterified free fatty acids.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Fasted concentration of non-esterified free fatty acids.
Presented as mmol/L.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Body fat percentage.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Body fat percentage determined via bioelectrical impedance analysis.
Presented as percentage.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Lean mass.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Determined via bioelectrical impedance analysis.
Presented in kilograms.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Waist circumference
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Waist circumference.
Presented as centimetres.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Systolic blood pressure.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Presented as mmHg.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Diastolic blood pressure.
時間枠：The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
Presented as mmHg.
|
The outcome will be measured as a single-time point assessment in a fasted state on day 1.
|
|
Light physical activity minutes per day.
時間枠：Over 7 days +/- the assessment day
|
Time spent participating in light physical activity.
Presented as minutes per day.
|
Over 7 days +/- the assessment day
|
|
Moderate-to-vigorous activity minutes per day.
時間枠：Over 7 days +/- the assessment day
|
Time spent participating in moderate-to-vigorous physical activity.
Presented as minutes per day.
|
Over 7 days +/- the assessment day
|
|
Daily steps.
時間枠：Over 7 days +/- the assessment day
|
Total daily steps.
Presented as steps per day.
|
Over 7 days +/- the assessment day
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Nicolette Bishop、Loughborough University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2020-1885-2140
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。